Vivoryon Therapeutics WKN: A2QJV6 ISIN: NL00150002Q7 Kürzel: VVY Forum: Aktien User: Support

2,0 -2,1

Auf lang und schwarz ja auf tradegate 5%

85 Prozent Minus und Spread von knapp 40 Prozent???

Habe 2000 stück gekauft

Sehe auch 2 Euro aut tradegate

Kwine Ahnung warum hier der kurs so angezeigt wird

Tradegate bid ask 2,0 - 2,1

Ich habe ein paar stück gekauft

Was glaubst du?

Überlege auch zu kaufen

Ausverkauf ist übertrieben

Schaut so aus als kommen ein paar köuger

Bin am Überlegen mit ner kleine n Position einzusteigen

Wer kauft nach?

Das war mein letztes Hochrisikoinvest. Bin mit Paion und Sensei schon auf die Schnauze gefallen....

Halle (Saale) / Munich, Germany, March 4, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced topline results from its Phase 2b European VIVIAD study of varoglutamstat (PQ912), an investigational oral glutaminyl cyclase (QPCT) inhibitor in development for the treatment of early Alzheimer’s disease (AD). The VIVIAD study did not meet its primary endpoint and did not show a statistically significant difference in change over time on cognition, as measured by a combined score (Z-score) of the Detection test, the Identification test and the ‘One Back’ test (attention and working memory domains) of the Cogstate neuropsychological test battery (NTB), called “Cogstate 3-item scale”. Additionally, the study did not meet key secondary endpoints measuring cognition (Cogstate Brief Battery, CBB, and complete Cogstate NTB), Instrumental Activities of Daily Living Questionnaire (A-IADL-Q) and electroencephalogram (EEG) global theta power. Varoglutamstat was generally well tolerated and showed rates similar to placebo of serious and severe treatment emergent adverse events (TEAEs), low discontinuation rates due to adverse events and no evidence of symptomatic ARIAs (amyloid-related imaging abnormalities) in the clinical setting.